More iPS cells in less time

A team at The Scripps Research Institute has found that a trio of small molecules can provide more than a 200-fold boost in the generation of induced pluripotent stem cells from human fibroblasts while cutting the generation time in half.¹

Fate Therapeutics Inc. has exclusively licensed the associated technology. Coupled with IP for an earlier fibroblast reprogramming protocol that only uses recombinant proteins,² which the biotech also obtained from Scripps, the company hopes to use the technologies to generate pharmaceutical-grade induced pluripotent stem (iPS) cells for therapeutic use and drug discovery on an industrial scale...